Overview

ZR-CHOP in DLBCL With Specific Gene Abnormality

Status:
Recruiting

Trial end date:
2026-01-04

Target enrollment:

Participant gender:

Summary

This is a phase 2, single center clinical trial. to evaluating the efficacy and safety of Zanubrutinib in combination with R-CHOP in newly diagnosed diffuse large B-cell lymphoma with specific gene abnormality.

Phase:

Phase 2

Details

Lead Sponsor:

Fudan University

Treatments:

Zanubrutinib